Power of Data Sharing

Reading time: 3 minutes Patty Spears One of the most valuable contributions a patient can make to science is to donate tumor tissue for research. It is important to use the tissue in research in a way that respects the intentions of the patient who donated it.  Tumor tissue can continue to add value to... Continue Reading →

Imaging-enabled insights from top radiopharmaceutical therapy trials

Reading time: 5 minutes Bethany Cooper Over the last 5 years, the radiopharmaceutical sector has seen significant global growth, with discoveries transforming cancer diagnostics and treatment through the targeted use of radiation. Methods to deliver radiation are becoming more precise, controlled, and effective, targeting tumor cells directly while sparing healthy tissue. Three seminal trials have... Continue Reading →

Promising trials: Lorlatinib for NSCLC

Reading time: 4 minutes Karli Norville In 2021, lung cancer was ranked as the number one cause of cancer deaths in the United States (1). The American Cancer Society reports that the 5-year survival rate of all Non-Small Cell Lung Cancer (NSCLC) patients is 26% (2). A recent study of the cancer drug Lorlatinib announced... Continue Reading →

Why Can’t I Be in This Clinical Trial?

Reading time: 5 minutes Patty Spears There are many barriers keeping patients out of clinical trials, even if they want to join the clinical trial.  There are multiple steps along the way and each step is a hurdle for patients.  A patient must first have physical access to the trial (structural barrier).  For example, I... Continue Reading →

Are Clinical Trials in Oncology Biased?

Reading time: 3 minutes Varshit Dusad Randomized controlled clinical trials (RCTs) are an important part of medical studies. Properly supervised trials act as the source of evidence for the safety and efficacy of new drugs, therapies, and medical devices. Hence, it is imperative that clinical trials are designed, conducted, and analysed in a robust and... Continue Reading →

How does a drug get approved?

Reading time: 5 minutes Bekah Schulz The Food and Drug Administration (FDA) is often criticized by patient advocacy groups for taking too much time to approve life-saving drugs. However, the FDA is a difficult situation; if they approve a drug too quickly and it turns out to be unsafe/ineffective, then people are upset. If they... Continue Reading →

It takes two brakes to stop cancer?

Reading time: 4 minutes Manisit Das In the past, we have discussed checkpoint inhibitors - therapies that block communication between cancer and immune cells, preventing cancer cells from evading the immune system. Dr. James Allison and Dr. Tasuku Honjo, who won the Nobel Prize in Medicine in 2018 for their pioneering work in cancer immunotherapy... Continue Reading →

Create a website or blog at WordPress.com

Up ↑